[1]
|
季大玺, 龚德华. 应重视连续性肾脏替代治疗在危重病中的应用[J]. 中国血液净化, 2007, 6(11): 581-583.
|
[2]
|
MacEwen, C., Watkinson, P. and Winearls, C. (2015) Circuit Life versus Bleeding Risk: The Impact of Achieved Activated Partial Thromboplastin Time versus Achieved Filtration Fraction. Therapeutic Apheresis and Dialy-sis, 19, 259-266. https://doi.org/10.1111/1744-9987.12253
|
[3]
|
Brandenburger, T., Dimski, T., Slowinski, T., et al. (2017) Renal Replacement Therapy and Anticoagulation. Best Practice & Research Clinical Anaesthesiology, 3, 387-401. https://doi.org/10.1016/j.bpa.2017.08.005
|
[4]
|
Monchi, M. (2017) Citrate Pathophysiology and Metabolism. Transfusion and Apheresis Science, 56, 28-30.
https://doi.org/10.1016/j.transci.2016.12.013
|
[5]
|
Morita, Y., Johnson, R.W., Dorn, R.E., et al. (1961) Regional Anticoagulation during Hemodialysis Using Citrate. The American Journal of the Medical Sciences, 1961, 32-43.
|
[6]
|
Mehta, R.L., McDonald, B.R., Aguilar, M.M., et al. (1990) Regional Citrate Anticoagulation for Continu-ous Arteriovenous Hemodialysis in Critically Ill Patients. Kidney International, 5, 976-981. https://doi.org/10.1038/ki.1990.300
|
[7]
|
严海燕, 黄雪敏, 李大亮, 等. 局部枸橼酸抗凝在重症急性肾损伤患者连续性肾脏替代治疗中的应用分析[J]. 实用中西医结合临床, 2022, 22(17): 31-33, 37. https://doi.org/10.13638/j.issn.1671-4040.2022.17.009
|
[8]
|
Morgera, S., Schneider, M., Slowinski, T., et al. (2009) A Safe Citrate Anticoagulation Protocol with Variable Treatment Efficacy and Excellent Control of the Acid-Base Status. Critical Care Medicine, 27, 2018-2024.
https://doi.org/10.1097/CCM.0b013e3181a00a92
|
[9]
|
Hetzel, G.R., Taskaya, G., Sucker, C., et al. (2006) Citrate Plasma Levels in Patients under Regional Anticoagulation in Continuous Venovenous Hemofiltration. American Journal of Kidney Diseases, 48, 806-811.
https://doi.org/10.1053/j.ajkd.2006.07.016
|
[10]
|
Durão, M.S., Monte, J.C., Batista, M.C., et al. (2008) The Use of Regional Citrate Anticoagulation for Continuous Venovenous Hemodiafiltration in Acute Kidney Injury. Critical Care Medicine, 36, 3024-3029.
https://doi.org/10.1097/CCM.0b013e31818b9100
|
[11]
|
Bai, M., Zhou, M., He, L., et al. (2015) Citrate versus Hep-arin Anticoagulation for Continuous Renal Replacement Therapy: An Updated Meta-Analysis of RCTs. Intensive Care Medicine, 41, 2098-2110.
https://doi.org/10.1007/s00134-015-4099-0
|
[12]
|
Slowinski, T., Morgera, S., Joannidis, M., et al. (2015) Safety and Efficacy of Regional Citrate Anticoagulation in Continuous Venovenous Hemodialysis in the Presence of Liver Failure: tHe Liver Citrate Anticoagulation Threshold (L-CAT) Observational Study. Critical Care, 19, Article No. 349. https://doi.org/10.1186/s13054-015-1066-7
|
[13]
|
Khwaja, A. (2012) KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clinical Practice, 120, c179-c184. https://doi.org/10.1159/000339789
|
[14]
|
吉彪. 枸橼酸体外抗凝技术在ICU急性肾损伤患者肾替代治疗中的临床应用研究[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2021. https://doi.org/10.27433/d.cnki.gxyku.2021.000796
|
[15]
|
Monchi, M., Berghmans, D., Ledoux, D., et al. (2004) Citrate vs. Heparin for Anticoagulation in Continuous Venovenous Hemofiltration: A Prospective Randomized Study. Intensive Care Medicine, 30, 260-265.
https://doi.org/10.1007/s00134-003-2047-x
|
[16]
|
Oudemans-van Straaten, H.M. (2010) Citrate Anticoagulation for Continuous Renal Replacement Therapy in the Critically Ill. Blood Purification, 29, 191-196. https://doi.org/10.1159/000245646
|
[17]
|
Liu, C., Mao, Z., Kang, H., et al. (2016) Regional Citrate versus Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Patients: A Meta-Analysis with Trial Se-quential Analysis of Randomized Controlled Trials. Critical Care, 20, Article No. 144. https://doi.org/10.1186/s13054-016-1299-0
|
[18]
|
Kalb, R., Kram, R., Morgera, S., et al. (2013) Regional Citrate Anticoagulation for High Volume Continuous Venovenous Hemodialysis in Surgical Patients with High Bleeding Risk. Therapeutic Apheresis and Dialysis, 17, 202-212.
https://doi.org/10.1111/j.1744-9987.2012.01101.x
|
[19]
|
Park, J.S., Kim, G.H., Kang, C.M., et al. (2011) Regional Anticoagulation with Citrate Is Superior to Systemic Anticoagulation with Heparin in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration. The Korean Journal of Internal Medicine, 26, 68-75. https://doi.org/10.3904/kjim.2011.26.1.68
|
[20]
|
Morabito, S., Pistolesi, V., Tritapepe, L., et al. (2012) Regional Cit-rate Anticoagulation in Cardiac Surgery Patients at High Risk of Bleeding: A Continuous Veno-Venous Hemofiltration Protocol with a Low Concentration Citrate Solution. Critical Care, 16, Article No. R111. https://doi.org/10.1186/cc11403
|
[21]
|
Shum, H.P., Chan, K.C. and Yan, W.W. (2012) Regional Citrate Anticoagu-lation in Predilution Continuous Venovenous Hemofiltration Using Prismocitrate 10/2 Solution. Therapeutic Apheresis and Dialysis, 16, 81-86.
https://doi.org/10.1111/j.1744-9987.2011.01001.x
|
[22]
|
Jacobs, R., Honore, P.M., Hendrickx, I. and Spapen, H.D. (2016) Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy: All Citrates Are Not Created Equal! Blood Purification, 42, 219-220.
https://doi.org/10.1159/000448801
|
[23]
|
Zhang, Z. and Hongying, N. (2012) Efficacy and Safety of Regional Cit-rate Anticoagulation in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy. Intensive Care Medi-cine, 38, 20-28.
https://doi.org/10.1007/s00134-011-2438-3
|
[24]
|
Klingele, M., Seiler, S., Poppleton, A., et al. (2014) The Gap be-tween Calculated and Actual Calcium Substitution during Citrate Anticoagulation in an Immobilised Patient on Renal Re-placement Therapy Reflects the Extent of Bone Loss—A Case Report. BMC Nephrology, 15, Article No. 163. https://doi.org/10.1186/1471-2369-15-163
|
[25]
|
Raimundo, M., Crichton, S., Lei, K., et al. (2013) Maintaining Normal Levels of Ionized Calcium during Citrate-Based Renal Replacement Therapy Is Associated with Stable Parathy-roid Hormone Levels. Nephron Clinical Practice, 124, 124-131. https://doi.org/10.1159/000355860
|
[26]
|
Khadzhynov, D., Dahlinger, A., Schelter, C., et al. (2017) Hyperlactatemia, Lactate Kinetics and Prediction of Citrate Accumulation in Critically Ill Patients Undergoing Continuous Renal Replace-ment Therapy with Regional Citrate Anticoagulation. Critical Care Medicine, 45, e941-e946. https://doi.org/10.1097/CCM.0000000000002501
|
[27]
|
Schultheiß, C., Saugel, B., Phillip, V., et al. (2012) Con-tinuous Venovenous Hemodialysis with Regional Citrate Anticoagulation in Patients with Liver Failure: A Prospective Observational Study. Critical Care, 16, Article No. R162.
https://doi.org/10.1186/cc11485
|
[28]
|
Kramer, L., Bauer, E., Joukhadar, C., et al. (2003) Citrate Pharmacokinetics and Metabolism in Cirrhotic and Noncirrhotic Critically Ill Patients. Critical Care Medicine, 31, 2450-2455.
https://doi.org/10.1097/01.CCM.0000084871.76568.E6
|
[29]
|
刘京鹤, 杜春静, 刘景院, 等. 肝衰竭合并急性肾损伤患者接受局部枸橼酸抗凝的持续肾脏替代治疗中发生代谢不良反应的危险因素[J]. 中国肝脏病杂志(电子版), 2022, 14(3): 45-52.
|
[30]
|
Meier-Kriesche, H.U.,Gitomer, J., Finkel, K., et al. (2001) Increased Total to Ionized Cal-cium Ratio during Continuous Venovenous Hemodialysis with Regional Citrate Anticoagulation. Critical Care Medicine, 29, 748-752.
https://doi.org/10.1097/00003246-200104000-00010
|
[31]
|
Saner, F.H., Treckmann, J.W., Geis, A., et al. (2012) Efficacy and Safety of Regional Citrate Anticoagulation in Liver Transplant Patients Requiring Post-Operative Renal Re-placement Therapy. Nephrology Dialysis Transplantation, 29, 1651-1657. https://doi.org/10.1093/ndt/gfr510
|